What We Do
the problem
the solution
patients
doctors
How We Do It
our approach
clinical trials
the test
publications
Who We Are
prolocor
our team
advisors
Newsroom
press releases
in the news
events
Get In Touch
info@prolocor.com

A novel diagnostic test to quantify FcyRIIa on the surface of platelets.

navigate down

Let's scratch the surface.

In the United States, atherosclerotic cardiovascular disease is a leading cause of death and disability for men, women, and people of most racial and ethnic groups.

let's dig deeper

There is a real unmet need.

Currently, there is no precise diagnostic tool that can effectively guide individualized therapy for patients with cardiovascular disease.

learn more

A big problem set us on an even bigger mission.

Our goal is to develop a more precise method and diagnostic tool for assessing and managing risk in cardiovascular disease.

learn how we plan to fulfill it
Picture of the pacient with doctor
Learn how we plan to help cardiovascular patients.
Picture of the pacient with doctor
See how our technology will empower physicians.

Meet the future of precision diagnostics.

An innovative diagnostic test that is being developed to help doctors make more informed treatment decisions.

discover our test
latest news
badge

May 20, 2026

Prolocor Announces Results of NIH-funded Study Demonstrating That Platelet FcγRIIa Identifies Cancer Patients at Increased Risk of Death and Thrombotic Events

read more

March 2, 2026

Prolocor® Research Named a “Top 10 Article of 2025” by the Journal of Invasive Cardiology

read more

November 03, 2025

Prolocor® Announces Publication in Journal of Invasive Cardiology

read more